BAM
ABBV icon

Bruderman Asset Management’s AbbVie ABBV Stock Holding History

Bruderman Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1.66M Sell
10,842
-834
-7% -$127K 2.98% 9
2022
Q1 		$1.89M Sell
11,676
-11,673
-50% -$1.7M 2.86% 10
2021
Q4 		$3.16M Sell
23,349
-45,508
-66% -$5.38M 2.42% 11
2021
Q3 		$7.43M Buy
68,857
+1,436
+2% +$164K 1.87% 17
2021
Q2 		$7.59M Buy
67,421
+1,287
+2% +$145K 2.35% 17
2021
Q1 		$7.16M Buy
66,134
+1,748
+3% +$187K 1.99% 17
2020
Q4 		$6.9M Buy
64,386
+21,464
+50% +$2.06M 2% 18
2020
Q3 		$3.76M Sell
42,922
-2,177
-5% -$205K 1.23% 29
2020
Q2 		$4.47M Buy
45,099
+848
+2% +$74.7K 1.48% 27
2020
Q1 		$3.25M Buy
44,251
+2,924
+7% +$249K 1.29% 28
2019
Q4 		$3.7M Sell
41,327
-3,145
-7% -$261K 1.16% 38
2019
Q3 		$3.79M Buy
+44,472
New +$3.05M 0.96% 41
2019
Q2 		– Sell
-1,287
Closed -$104K – 117
2019
Q1 		$104K Sell
1,287
-110
-8% -$9K 0.02% 192
2018
Q4 		$129K Buy
1,397
+1,033
+284% +$90.8K 0.03% 144
2018
Q3 		$34K Buy
364
+117
+47% +$11.1K 0.01% 220
2018
Q2 		$23K Sell
247
-279
-53% -$27.2K 0.01% 259
2018
Q1 		$50K Sell
526
-79,547
-99% -$8.74M 0.01% 199
2017
Q4 		$7.74M Sell
80,073
-4,699
-6% -$443K 1.97% 16
2017
Q3 		$7.53M Sell
84,772
-31,216
-27% -$2.38M 1.95% 18
2017
Q2 		$8.41M Buy
115,988
+5,271
+5% +$354K 2.25% 15
2017
Q1 		$7.21M Sell
110,717
-1,969
-2% -$124K 2.08% 17
2016
Q4 		$7.06M Buy
112,686
+19,759
+21% +$1.21M 2.13% 13
2016
Q3 		$5.86M Sell
92,927
-72
-0.1% -$4.66K 1.75% 18
2016
Q2 		$5.76M Buy
92,999
+39,212
+73% +$2.39M 1.8% 18
2016
Q1 		$3.07M Buy
53,787
+49,818
+1,255% +$2.78M 1.07% 26
2015
Q4 		$235K Buy
3,969
+11
+0.3% +$634 0.09% 109
2015
Q3 		$215K Buy
3,958
+64
+2% +$4.17K 0.08% 103
2015
Q2 		$262K Buy
3,894
+9
+0.2% +$588 0.1% 97
2015
Q1 		$227K Buy
+3,885
New +$235K 0.09% 101

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bruderman Asset Management's ABBV Position: Q2 2022 in Review

Bruderman Asset Management reduced its AbbVie (ABBV) stake by 7.1% in Q2 2022, selling an estimated $127K and leaving 10,842 shares worth $1.66M. The position accounts for 2.98% of the portfolio, ranked #9.

Bruderman Asset Management first reported a position in ABBV in Q1 2015 and has held it in 29 quarters since. The position peaked at $8.41M in Q2 2017. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

  • Bruderman Asset Management held 10,842 shares of AbbVie worth $1.66M as of Q2 2022.
  • Bruderman Asset Management sold 834 AbbVie shares in Q2 2022, an estimated $127K.
  • AbbVie made up 2.98% of Bruderman Asset Management's portfolio in Q2 2022, its #9 holding.
  • Bruderman Asset Management first reported a position in AbbVie in Q1 2015 and has held it in 29 quarters since.
  • Bruderman Asset Management's AbbVie position peaked at $8.41M in Q2 2017.
  • 3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on Bruderman Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.